TY - JOUR T1 - Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial JF - medRxiv DO - 10.1101/2022.12.15.22283488 SP - 2022.12.15.22283488 AU - Susanna Naggie AU - David R. Boulware AU - Christopher J. Lindsell AU - Thomas G. Stewart AU - Stephen C. Lim AU - Jonathan Cohen AU - David Kavtaradze AU - Arch P. Amon AU - Ahab Gabriel AU - Nina Gentile AU - G. Michael Felker AU - Russell L. Rothman AU - Dushyantha Jayaweera AU - Matthew W. McCarthy AU - Mark Sulkowski AU - Sybil Wilson AU - Allison DeLong AU - April Remaly AU - Rhonda Wilder AU - Sean Collins AU - Sarah E. Dunsmore AU - Stacey J. Adam AU - Florence Thicklin AU - George J. Hanna AU - Adit A. Ginde AU - Mario Castro AU - Kathleen McTigue AU - Elizabeth Shenkman AU - Adrian F. Hernandez AU - the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/12/15/2022.12.15.22283488.abstract N2 - Background Whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) remains unknown. Our objective was to evaluate the effectiveness of ivermectin, dosed at 600 μg/kg, daily for 6 days compared with placebo for the treatment of early mild to moderate COVID-19.Methods ACTIV-6, an ongoing, decentralized, randomized, double-blind, placebo-controlled, platform trial, was designed to evaluate repurposed therapies in outpatients with mild to moderate COVID-19. A total of 1206 participants age ≥30 years with confirmed COVID-19, experiencing ≥2 symptoms of acute infection for ≤7 days, were enrolled from February 16, 2022, through July 22, 2022, with follow-up data through November 10, 2022, at 93 sites in the US. Participants were randomized to ivermectin, with a maximum targeted dose of 600 μg/kg (n=602), daily vs. placebo daily (n=604) for 6 days. The primary outcome was time to sustained recovery, defined as at least 3 consecutive days without symptoms. The 7 secondary outcomes included a composite of hospitalization, death, or urgent/emergent care utilization by day 28.Results Among 1206 randomized participants who received study medication or placebo, median (interquartile range) age was 48 (38–58) years; 713 (59%) were women; and 1008 (84%) reported ≥2 SARS-CoV-2 vaccine doses. Median time to recovery was 11 (11–12) days in the ivermectin group and 11 (11–12) days in the placebo group. The hazard ratio (HR) (95% credible interval [CrI], posterior probability of benefit) for improvement in time to recovery was 1.02 (0.92–1.13; P[HR>1]=0.68). In those receiving ivermectin, 34 (5.7%) were hospitalized, died, or had urgent or emergency care visits compared with 36 (6.0%) receiving placebo (HR 1.0, 0.6– 1.5; P[HR<1]=0.53). In the ivermectin group, 1 participant died and 4 were hospitalized (0.8%); 2 participants (0.3%) were hospitalized in the placebo group and there were no deaths. Adverse events were uncommon in both groups.Conclusions Among outpatients with mild to moderate COVID-19, treatment with ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo did not improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.Trial registration ClinicalTrials.gov Identifier: NCT04885530.Competing Interest StatementNaggie: Reports grants from NIH, the sponsor for this study, during the conduct of the study; Institutional research grants from Gilead Sciences, AbbVie; Consulting fees from Pardes Biosciences; Scientific advisor/Stock options from Vir Biotechnology; Consulting with no financial payment from Silverback Therapeutics; DSMB fees from Personal Health Insights, Inc; Event adjudication committee fees from BMS/PRA outside the submitted work. Boulware: Reports grants from NIH during the conduct of the study. Lindsell: Reports institutional grants from NCATS during the conduct of the study; Institutional grants from NIH, CDC, and DoD; Contract with institution for research services from Endpoint Health, bioMerieux, Entegrion Inc, Abbvie, and Astra Zeneca outside the submitted work; Dr Lindsell has a patent for risk stratification in sepsis and septic shock issued to Cincinnati Children's Hospital Medical Center. Stewart: Reports grants from NIH NCATS during the conduct of the study; Grants from NIH outside the submitted work. Lim: NIH funding for this study, CDC funding for other studies, Integrated Neurologics for phase 2 device trial. Cohen: Nothing to report. Kavtaradze: Nothing to report. Amon: Nothing to report. Gabriel: Nothing to report. Gentile: Reports personal fees from Duke University for protocol development and oversight during the conduct of the study; grants from NIH outside the submitted work. Felker: Reports institutional research grants from NIH during the conduct of the study and from Novartis outside the submitted work. Rothman: Reports institutional research grants from NIH, PCORI, AHRQ, and CDC during the conduct of the study. Spouse owns stock in Moderna unrelated to the current work. Jayaweera: Reports grants from NCATS PI-Ralph Sacco during the conduct of the study; Grants from Gilead, Pfizer, Janssen, and Viiv; Consulting fees from Theratechnologies outside the submitted work. McCarthy: Nothing to report. Sulkowski: Reports advisory board fees from AbbVie, Gilead, GSK, Atea, Antios, Precision Bio, Viiv, and Virion; Institutional grants from Janssen outside the submitted work. Wilson: Reports institutional research funding from the National Center for Advancing Translational Sciences (3U24TR001608) during the conduct of the study. DeLong: Reports institutional research funding from the National Center for Advancing Translational Sciences (3U24TR001608) during the conduct of the study. Remaly: Reports institutional research funding from the National Center for Advancing Translational Sciences (3U24TR001608) during the conduct of the study. Wilder: Reports institutional research funding from the National Center for Advancing Translational Sciences (3U24TR001608) during the conduct of the study. Collins: Reports grant funding from NHLBI and personal fees from Vir Biotechnology during the conduct of the study. Dunsmore: Nothing to report. Adam: Reports other from US Government Funding through Operation Warp Speed during the conduct of the study. Thicklin: Nothing to report. Hanna: Reports grants from US Biomedical Advanced Research & Development Authority contract to Tunnell Government Services for consulting services during the conduct of the study; Personal fees from Merck & Co. and AbPro outside the submitted work. Ginde: Reports grants from NIH during the conduct of the study; Grants from NIH, CDC, DoD, AbbVie (investigator-initiated), and Faron Pharmaceuticals (investigator-initiated) outside the submitted work. Castro: Reports institutional grant funding from NIH, ALA, PCORI, AstraZeneca, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi; Speaker/Consultant fees from Grant Funding, Genentech, Teva, Sanofi-Aventis; Consultant fees from Merck, Novartis, Arrowhead, OM Pharma, Allakos; Speaker honorarium from Amgen, AstraZeneca, GSK, Regeneron; Royalties from Elsevier all outside the submitted work. McTigue: Reports grants from NIH Research Subcontract to the University of Pittsburgh during the conduct of the study; Research contract to the University of Pittsburgh from Pfizer, and Janssen outside the submitted work. Shenkman: Nothing to report. Hernandez: Reports grants from American Regent, Amgen, Boehringer Ingelheim, Merck, Verily, Somologic, and Pfizer; Personal fees from AstraZeneca, Boston Scientific, Cytokinetics, Bristol Myers Squibb, and Merck outside the submitted work. Clinical TrialClinicalTrials.gov Identifier: NCT04885530.Funding StatementACTIV-6 is funded by the National Center for Advancing Translational Sciences (NCATS) (3U24TR001608-06S1). Additional support for this study was provided by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No.75A50122C00037). The Vanderbilt University Medical Center Clinical and Translational Science Award from NCATS (UL1TR002243) supported the REDCap infrastructure.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesACTIV-6 is a platform trial using shared placebos. On completion of the platform trial when there is no risk of unblinding across study arms the data will be made publicly available by depositing it in an approved data repository such as NHLBI BioData Catalyst. ER -